We are live on ! Find out more
MDCO

Medicines Co
MDCO

Delisted

MDCO was delisted on the 3rd of January, 2020.

184 hedge funds and large institutions have $2.83B invested in Medicines Co in 2018 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 71 increasing their positions, 54 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 54

13% more funds holding in top 10

Funds holding in top 10: 89 (+1)

2% less funds holding

Funds holding: 188184 (-4)

11% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 27

13% less call options, than puts

Call options by funds: $58M | Put options by funds: $66.6M

20% less capital invested

Capital invested by funds: $3.52B → $2.83B (-$688M)

Holders
184
Holders Change
-4
Holders Change %
-2.13%
% of All Funds
4.21%
Holding in Top 10
9
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+12.5%
% of All Funds
0.21%
New
24
Increased
71
Reduced
54
Closed
27
Calls
$58M
Puts
$66.6M
Net Calls
-$8.67M
Net Calls Change
-$54.7M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$331M +$4.79M +127,139 +1%
BlackRock
2
BlackRock
New York
$330M +$13.8M +366,074 +3%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$308M +$690K +18,322 +0.2%
Vanguard Group
4
Vanguard Group
Pennsylvania
$200M +$6.13M +162,702 +2%
Westfield Capital Management
5
Westfield Capital Management
Massachusetts
$113M +$19.1M +506,028 +15%
AH
6
Aviva Holdings
Bahamas
$113M
PC
7
PointState Capital
New York
$87.6M -$40.8M -1,083,014 -27%
PHS
8
PFM Health Sciences
California
$76.6M +$17.8M +472,643 +23%
BM
9
Bridger Management
New York
$70M -$9.99M -265,275 -10%
State Street
10
State Street
Massachusetts
$66.1M +$6.97M +185,033 +9%
CCM
11
Camber Capital Management
Massachusetts
$59.8M
SPC
12
Slate Path Capital
New York
$59.7M +$9.98M +265,000 +15%
SCM
13
Sarissa Capital Management
Connecticut
$57.5M
IAM
14
Iridian Asset Management
Connecticut
$56.2M -$8.46M -224,652 -11%
PI
15
Putnam Investments
Massachusetts
$56M -$14.3M -379,306 -17%
TBC
16
Three Bays Capital
Massachusetts
$55.3M +$18.4M +489,262 +36%
Macquarie Group
17
Macquarie Group
Australia
$46.6M +$10.6M +281,213 +22%
BC
18
Boxer Capital
California
$41.9M +$5.65M +150,000 +12%
MC
19
Maverick Capital
Texas
$40.8M +$6.01M +159,556 +13%
GC
20
Greenlight Capital
New York
$28.4M -$1.93M -51,200 -5%
Northern Trust
21
Northern Trust
Illinois
$27.9M +$986K +26,169 +3%
Invesco
22
Invesco
Georgia
$27.7M +$14.9M +396,660 +75%
Bank of America
23
Bank of America
North Carolina
$26.3M +$1.08M +28,640 +3%
PA
24
Pinnacle Associates
New York
$24.4M -$4.86M -129,068 -14%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$23.1M +$899K +23,852 +3%

MDCO Hedge Fund Activity: Q3 2018 in Review

184 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q3 2018, worth a combined $2.83B — down 20% from $3.52B a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of MDCO and 24 opened new positions — a net loss of 3 holders — while 54 trimmed existing stakes and 71 added.

The largest buyer was Westfield Capital Management, adding an estimated $19.1M. The largest seller was PointState Capital, cutting an estimated $40.8M.

  • 184 institutional investors held Medicines Co (MDCO) as of Q3 2018, down from 188 in Q2 2018.
  • Funds reported $2.83B of Medicines Co stock for Q3 2018, down 20% quarter-over-quarter.
  • 24 funds opened new Medicines Co positions in Q3 2018 and 27 closed out, a net change of -3 holders.
  • The largest Medicines Co buyer in Q3 2018 was Westfield Capital Management, an estimated $19.1M added.
  • The largest Medicines Co seller in Q3 2018 was PointState Capital, an estimated $40.8M sold.

Based on aggregated 13F filings for Q3 2018.